GSK’s gepotidacin meets primary efficacy endpoint of Phase 3 trial in GC
GSK’s oral antibiotic candidate gepotidacin has met the primary efficacy endpoint of the EAGLE-1 Phase 3 trial in uncomplicated urogenital gonorrhoea (GC), a sexually transmitted infection caused by